Emergent Biosolutions Inc (EBS): Emergent Biosciences Finally Expanding ... Seeking Alpha The anti-CD37 monoclonal antibody is in a Phase 2 combination study with Bendamustine in relapsed CLL patients. Otlertuzumab is also in a Phase 1b frontline CLL trial in combination with rituximab. Emergent will present preliminary data from both ... |
